title: "Protecting Children from Mosquito Diseases in Europe" date: "2026-04-03" excerpt: "Children face unique risks from mosquito-borne diseases in Europe. Learn about age-specific dangers, vaccine limitations for under-12s, and physical barriers." category: "diseases" author: "Mosticare Editorial"
Protecting Children from Mosquito-Borne Diseases in Europe
By Mosticare Editorial | Published 2026-04-03
As mosquito-borne diseases become the "new normal" in Europe, parents face an increasingly urgent question: how do I protect my children? The ECDC and the WHO Regional Office for Europe specifically identify children as a vulnerable group requiring targeted protection. With vaccines either unavailable, restricted, or suspended for most mosquito-borne diseases, and chemical repellents posing their own concerns for young skin, physical barriers and environmental management have never been more important.
Why Children Are Especially Vulnerable
Immature Immune Systems
Children's immune systems are still developing, making them less able to mount an effective response to viral infections. Dengue, in particular, can be more severe in children. According to clinical literature on mosquito-borne diseases and their impact on children, paediatric dengue infections carry a higher risk of progressing to severe dengue (dengue haemorrhagic fever or dengue shock syndrome) compared with adult infections.
Higher Exposure
Children spend more time outdoors -- playing in gardens, parks, schoolyards, and playgrounds -- precisely during the hours when tiger mosquitoes (Aedes albopictus) are most active. Their smaller body surface area relative to adults also means a higher concentration of mosquito bites per kilogram of body weight.
Less Self-Protective Behaviour
Young children cannot independently take preventive measures. They do not apply their own repellent, are less likely to wear protective clothing in warm weather, and may not recognise or report mosquito bites. This makes parental vigilance and environmental measures critical.
Vulnerability to Specific Diseases
- Dengue: Children experiencing a second infection with a different dengue serotype face elevated risk of severe disease. As dengue becomes more common in Europe, the probability of repeat infections over a child's lifetime increases.
- West Nile virus: While neuroinvasive disease is more common in the elderly, children with immunodeficiencies are at heightened risk. As the ECDC mosquito-borne disease advisory notes, immunocompromised individuals, including children undergoing cancer treatment, should take particular precautions.
- Zika: While most children experience mild symptoms, the impact on pregnant adolescents can be devastating due to the microcephaly risk.
- Chikungunya: Although chronic joint pain is more common in adults, children can experience significant acute illness with high fever and rash.
Vaccine Limitations for Children
One of the most concerning aspects of Europe's mosquito-borne disease landscape is the lack of vaccine options for children.
Dengue Vaccines
Qdenga (TAK-003) is approved by the European Medicines Agency but is indicated for individuals aged 4 years and older. It is not widely available for routine paediatric use in Europe, and its effectiveness varies by dengue serotype and prior infection status. Dengvaxia (the older vaccine) is restricted to individuals with prior confirmed dengue infection due to safety concerns, and is not recommended for seronegative children.
Chikungunya Vaccine
The IXCHIQ vaccine was approved for adults aged 18 and over. It was never authorised for use in children. Moreover, the vaccine has been suspended by the US FDA and restricted in Europe due to serious adverse events in adults, meaning no chikungunya vaccine is currently available for any age group.
West Nile Virus Vaccine
No vaccine exists for West Nile virus in humans of any age. Vaccine development has stalled at the clinical trial stage.
Zika Vaccine
No Zika vaccine has been approved for human use.
The Bottom Line
For the foreseeable future, European children have no reliable pharmaceutical protection against the mosquito-borne diseases circulating on the continent. This reality places the entire burden of prevention on bite avoidance and vector control.
The Case for Physical Barriers
Given the limitations of vaccines and the concerns about chemical repellents for young children, physical barriers represent the most effective, safest, and most sustainable approach to protecting children from mosquito-borne diseases.
Why Physical Barriers Excel for Children
- No chemical exposure: Physical barriers -- screens, nets, enclosures -- work without any contact with a child's skin, eliminating concerns about repellent toxicity and skin sensitivity.
- Continuous protection: Once installed, physical barriers provide 24-hour protection without reapplication.
- No age restrictions: Unlike chemical repellents, which have specific age and concentration limitations, physical barriers are safe for newborns, infants, toddlers, and children of all ages.
- Effective against all vector species: The same screen that blocks Aedes albopictus during the day also blocks Culex pipiens at night, providing comprehensive coverage against dengue, chikungunya, Zika, and West Nile virus.
Practical Physical Barrier Solutions
In the home:
- Install fine-mesh screens on all windows and doors. Standard screen mesh should have openings no larger than 1.2mm x 1.2mm to exclude tiger mosquitoes, which are smaller than common house mosquitoes.
- Use mosquito nets over cribs, cots, and children's beds, particularly in ground-floor bedrooms.
- Ensure screens are intact -- even small tears can allow mosquitoes to enter.
In outdoor play areas:
- Consider screened enclosures for patios, terraces, and garden play areas.
- Use pop-up mosquito nets over sandboxes, paddling pools, and outdoor play spaces.
- Position fans in outdoor areas -- air movement disrupts mosquito flight patterns.
For pushchairs and prams:
- Use fine-mesh mosquito nets specifically designed for pushchairs when walking in areas with known tiger mosquito activity.
For travel:
- Carry portable mosquito nets for use in holiday accommodations that may lack adequate screening.
- Choose accommodations with screened or air-conditioned rooms.
Chemical Repellents: Age-Specific Guidance
When physical barriers are insufficient, repellents may be used with appropriate caution. The WHO advises following product-specific age recommendations. General guidance:
- Under 2 months: Do not use chemical repellents. Rely entirely on physical barriers (nets, clothing, screens).
- 2 months to 3 years: Use repellents sparingly and only on exposed skin. Apply to hands first and then to the child. Avoid hands, eyes, mouth, and any broken skin. Low-concentration DEET (10-20%) or icaridin products are generally recommended by European health authorities.
- 3 years and older: Standard repellents can be used following product instructions. Reapply as directed, especially after swimming or sweating.
Important: Never apply repellent under clothing, and always wash repellent off when the child comes indoors.
Environmental Management: Every Family's Role
Eliminating mosquito breeding sites around your home is one of the most impactful actions any family can take. Tiger mosquitoes breed in tiny amounts of standing water -- as little as a bottlecap:
- Weekly routine: Walk around your property weekly and empty any water-collecting containers: plant saucers, toys, watering cans, buckets, pet bowls, wheelbarrows.
- Maintain gutters: Clogged gutters are prolific mosquito breeding sites. Clean them regularly.
- Cover water storage: Rain barrels, cisterns, and water tanks should be covered with fine mesh.
- Swimming pools and ponds: Maintain proper chlorination or filtration. Untreated water features become mosquito factories.
- Involve children: Teaching children to identify and eliminate standing water is a valuable life skill in an era of expanding mosquito-borne disease.
What Paediatricians Recommend
The consensus among European paediatric and public health authorities can be summarised in three priorities:
- Physical barriers first: Screens, nets, and protective clothing are the foundation of child protection.
- Environmental action: Eliminate breeding sites to reduce mosquito populations at the source.
- Chemical repellents as a supplement: Use age-appropriate repellents when physical barriers alone are insufficient, particularly during outdoor activities in high-risk areas.
The Nemours KidsHealth resource on mosquito-borne diseases emphasises that prevention is entirely in parents' hands, given the absence of paediatric vaccines for most mosquito-borne diseases in Europe.
Frequently Asked Questions
At what age can I use mosquito repellent on my child?
Most health authorities advise against using chemical repellents on infants under 2 months of age. For children aged 2 months to 3 years, use low-concentration products sparingly on exposed skin only. Always follow the specific product's age recommendations.
Are mosquito-borne diseases dangerous for children?
Yes. Children face higher risks of severe dengue, and immunocompromised children are vulnerable to neuroinvasive West Nile virus. Chikungunya can cause significant acute illness in children. Prevention through bite avoidance is critical.
What is the best way to protect a baby from mosquitoes?
Physical barriers are the safest and most effective approach for babies: fine-mesh mosquito nets over cribs and pushchairs, window and door screens in the home, and lightweight clothing covering arms and legs.
About Mosticare: Mosticare develops chemical-free mosquito protection solutions for homes, businesses, and communities across Europe. Our mission: a green, mosquito-free life for every European. Learn more
Sources cited in this article:
- ECDC - World Mosquito Day 2025: Europe sets new records
- WHO Europe - Public health advice on mosquito-borne diseases
- ECDC - Mosquito-borne diseases: an increasing risk in Europe
- International Journal of Clinical Pediatrics - Mosquito-borne diseases and their impact on children
- Nemours KidsHealth - Mosquito-borne diseases
- FDA - IXCHIQ vaccine suspension